FrontPage is India's Stock Market Social Network
Join 50,000+ Traders and Investors

SHILPAMED

627.25
+0.2 (0.03%)
Updated 12:30 30/07 IST

SHILPAMED Buy or Sell - FrontPage Forums

4 Users have submitted 4 trade ideas of Rs. 537,860 for SHILPAMED
Disclaimer
100% Bullish
0% Bearish

SHILPAMED Buy or Sell - Brokerage Reports

No. of reports in last year
0
No. of analysts
0
Average Consensus Forecast
Consensus Potential
0.00%
See SHILPAMED Share Price Targets >>

SHILPAMED Ratings

Long term SHILPAMED rating by FrontPage users
0/5 (0 Ratings)0
Find answers to all your questions on live SHILPAMED message board: Is SHILPAMED buy or sell? Should I buy SHILPAMED shares? Why are SHILPAMED shares falling? Should I invest in SHILPAMED stock?

  1. Home
  2. SHILPAMED Forum

SHILPAMED Share Price Discussion


Type
Buy
Instrument
SHILPAMED
Entry Price
₹626
Price@Trade
₹630.95
Target Price
₹645
Stop Price
₹621
Valid Till
Jul 30, 2021 3:20 AM
Margin
₹313,000 approx for 500 Qty
Status
Waiting for entry

Like
Reply
swap_vert
Trade

Type
Buy
Instrument
SHILPAMED
Entry Price
₹622
Price@Trade
₹622.5
Target Price
₹650
Stop Price
₹617
Valid Till
Jul 29, 2021 3:20 AM
Margin
₹311,000 approx for 500 Qty
Status
Expired before entry

Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Yesterday 8:51 AM

Update
Expired before entry
Price @ Update
₹628.2

Type
Buy
Instrument
SHILPAMED
Entry Price
₹618
Price@Trade
₹618.2
Target Price
₹645
Stop Price
₹615
Valid Till
Jul 28, 2021 3:20 AM
Margin
₹309,000 approx for 500 Qty
Status
Exited
Exit Price
₹617.8
Net P&L
-₹100 (-0.03%)

Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jul 28 7:24 AM

Update
Trade Entered
Entry Price
₹618
Nagaraj @nagaraj-rJtxND7AD
Jul 28 7:49 AM

Update
Exited
Exit Price
₹617.8
Net P&L
-₹100 (-0.03%)
Like
Reply

Type
Sell
Instrument
SHILPAMED
Entry Price
₹692
Price@Trade
₹664.95
Target Price
₹675
Stop Price
₹696
Valid Till
Jul 26, 2021 3:20 AM
Margin
₹346,000 approx for 500 Qty
Status
Exited before entry

Like
Reply (1)
swap_vert
Trade
See all replies
Nagaraj @nagaraj-rJtxND7AD
Jul 26 7:21 AM

Update
Exited before entry
Price @ Update
₹654.25
S
Reputation: 96 • Jul 23 6:13 AM
Like
Reply

Type
Sell
Instrument
SHILPAMED
Entry Price
₹638.7
Price@Trade
₹638.7
Target Price
₹538.7
Stop Price
₹738.7
Valid Till
Jul 22, 2022 3:20 AM
Margin
₹127,740 approx for 200 Qty
Status
Exited
Exit Price
₹638.4
Net P&L
+₹60 (+0.05%)
Like
Reply (1)
swap_vert
Trade
See all replies
Dwarkesh Panchal @dwarkesh
Jul 23 7:36 AM

Update
Exited
Exit Price
₹638.4
Net P&L
+₹60 (+0.05%)

Type
Sell
Instrument
SHILPAMED
Entry Price
₹645
Price@Trade
₹641.5
Target Price
₹630
Stop Price
₹650
Valid Till
Jul 23, 2021 3:20 AM
Margin
₹193,500 approx for 300 Qty
Status
Expired before entry

Like
Reply (1)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jul 23 8:50 AM

Update
Expired before entry
Price @ Update
₹630.3
Like
Reply

Type
Sell
Instrument
SHILPAMED
Entry Price
₹644.3
Price@Trade
₹644.3
Target Price
₹544.25
Stop Price
₹744.25
Valid Till
Jul 22, 2022 3:20 AM
Margin
₹193,290 approx for 300 Qty
Status
Exited
Exit Price
₹638.15
Net P&L
+₹1,845 (+0.95%)
Like
Reply (1)
swap_vert
Trade
See all replies
Dwarkesh Panchal @dwarkesh
Jul 23 7:36 AM

Update
Exited
Exit Price
₹638.15
Net P&L
+₹1,845 (+0.95%)
S
Reputation: 96 • Jul 22 7:31 AM
Like
Reply
S
Reputation: 96 • Jul 22 2:54 AM
Like
Reply
Like
Reply
A
Reputation: 0 • Jul 19 7:09 AM

Type
Buy
Instrument
SHILPAMED
Entry Price
₹610
Price@Trade
₹610
Target Price
₹705
Stop Price
₹563
Valid Till
Jul 19, 2022 3:20 AM
Margin
₹61,000 approx for 100 Qty
Status
Active
Like
Reply
swap_vert
Trade
S
Reputation: 3,504 • Jul 15 5:24 AM
Shivansh in SHILPAMED
#SHILPAMED Same Pattern, Buy around 591-595 S...
4
Reply

Type
Buy
Instrument
SHILPAMED
Entry Price
₹589.5
Price@Trade
₹593.4
Target Price
₹606
Stop Price
₹583
Valid Till
Jul 15, 2021 3:20 AM
Margin
₹58,950 approx for 100 Qty
Status
Exited before entry
Like
Reply (1)
swap_vert
Trade
See all replies

Update
Exited before entry
Price @ Update
₹604.5

#SHILPAMED : The company approved the transfer of API business consisting of Unit-1 and Unit-2 situated at Raichur, Karnataka by way of slump sale to a wholly owned subsidiary of the company.
1
Reply

Type
Buy
Instrument
SHILPAMED
Entry Price
₹612.5
Price@Trade
₹612.5
Target Price
₹629
Stop Price
₹600  ₹610
Valid Till
Jul 13, 2021 3:20 AM
Margin
₹612,500 approx for 1000 Qty
Status
Stoploss Hit
Exit Price
610.0
Net P&L
-₹2,500 (-0.41%)
Like
Reply (2)
swap_vert
Trade
See all replies

Update
Stoploss Trailed
Price @ Update
₹610.45
Original SL
₹600
New SL
610.0
TrackerBot @trackerbot
Jul 13 4:51 AM

Update
Stoploss Hit
Exit Price
610.0

Type
Sell
Instrument
SHILPAMED
Entry Price
₹615
Price@Trade
₹613.35
Target Price
₹600
Stop Price
₹622
Valid Till
Jul 13, 2021 3:20 AM
Margin
₹307,500 approx for 500 Qty
Status
Validity Over
Exit Price
₹603.85
Net P&L
+₹5,575 (+1.81%)

Like
Reply (2)
swap_vert
Trade
See all replies
TrackerBot @trackerbot
Jul 13 3:11 AM

Update
Trade Entered
Entry Price
₹615
TrackerBot @trackerbot
Jul 13 8:50 AM

Update
Validity Over
Exit Price
₹603.85
Net P&L
+₹5,575 (+1.81%)
N
Reputation: 15,707 • Jul 13 2:56 AM
Sensex gains in early trade, Nifty above 15,750; Ashoka Buildcon rises 4%, Shilpa Medicare 3%
The S&P BSE Sensex index rose as much as 344 points to touch 52,716.83 in the first few minutes of trade, and the broader NSE Nifty 50 benchmark climbed to as high as 15,796.25, up 104 points from its previous close.
The Economic Times
Like
Reply
Join FrontPage
FrontPage is India's favorite stock discussions community
Join 2,00,000 Indian traders and discuss trades, strategies, news & views on any stock.
  • SHILPAMED - Share Price - Fundamentals

    keyboard_arrow_down
    Market Capitalization2,772.63
    Enterprise Value2,841.7
    Price to Earnings28.49
    Price to Book Value2.16
    Return on Capital Employed0.13
    Return on Equity0.12
    Face Value1
    Dividend YieldNA
  • SHILPAMED - Brokerage Reports

    keyboard_arrow_down
    DateBrokerageCallTarget
    8-Feb-19Motilal OswalBuy480
    21-Jan-19Motilal OswalBuy620
    15-Nov-18Motilal OswalBuy575
    14-Aug-18Motilal OswalBuy620
    3-Apr-18Motilal OswalBuy686
    SHILPAMED Brokerage Price Target
  • SHILPAMED Share Price - Historical (₹)

    keyboard_arrow_down
    DateOpenHighLowClose
    Jul 29631.65636.95622627.05
    Jul 28628.7643.05606630.65
    Jul 27660663.15615.05623.4
    Jul 26625.1666.6625.1650.2
    Jul 23646651.5624.95631.05
  • SHILPAMED Share Price - Daily Moving Averages (DMA)

    keyboard_arrow_down
    20 Day Moving Average₹596.19
    30 Day Moving Average₹579.3
    50 Day Moving Average₹563.79
    100 Day Moving Average₹479.23
    200 Day Moving Average₹460.57
  • SHILPAMED - Profit And Loss

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Revenue741733.420.01
    Operating Profit179182.23-0.02
    Profit Before Tax167170.29-0.02
    Net Income133126.590.05
  • SHILPAMED - Balance Sheet

    keyboard_arrow_down
    CONSOLIDATEDMar-19Mar-18 % Change
    Shareholder's Funds1,2811,1570.11
    Total Liabilities387425-0.09
    Total Assets1,6681,5820.05
  • SHILPAMED - Cash Flow

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17 % Change
    Cash from Operating Activity5438.290.41
    Cash from Investing Activity-13-266.89-0.95
    Cash from Financing Activity-62316.32-1.2
    Net Cash Flow-2087.72-1.23
  • SHILPAMED - Ratios

    keyboard_arrow_down
    CONSOLIDATEDMar-18Mar-17
    Return on Assets0.080.09
    Return on Equity0.120.13
    Return on Capital Employed0.130.15
  • SHILPAMED - 3 year Growth

    keyboard_arrow_down
    3 Year CAGR Growth in Revenue0.31
    3 Year CAGR Growth in Operating Profit0.31
    3 Year CAGR Growth in EBIDTA0.42
    3 Year CAGR Growth in Net Income0.58
    3 Yr CAGR Growth - Diluted EPS-0.25
  • SHILPAMED - 5 year Growth

    keyboard_arrow_down
    5 Year CAGR Growth in Revenue1.26
    5 Year CAGR Growth in Operating Profit1.74
    5 Year CAGR Growth in EBIDTA1.87
    5 Year CAGR Growth in Net Income1.89
    3 Yr CAGR Growth - Diluted EPS-0.13
  • SHILPAMED - Recent News

    keyboard_arrow_down
    NewsBot
    Jun 4 2:16 AM
    Buy Shilpa Medicare, target price Rs 605: Yes Securities
    The Economic Times
    NewsBot
    May 18 6:11 AM
    Shilpa Medicare zooms 26% in 2 days after DRL vaccine deal
    The Economic Times
    NewsBot
    May 18 12:56 PM
    Sputnik pact with DRL sends Shilpa Medicare to 7-month high
    The Economic Times
    NewsBot
    May 17 6:16 AM
    Shilpa Medicare jumps 13% after inking vaccine deal with DRL
    The Economic Times
    NewsBot
    May 17 4:16 AM
    Shilpa Medicare arm inks pact with Dr Reddy's to manufacture Sputnik V vaccine
    The Economic Times
    NewsBot
    Apr 8 3:11 AM
    Insurance and mutual fund monoliths to come out of India in next 10-20 years: Ajay Bagga
    The Economic Times
    NewsBot
    Apr 7 5:46 AM
    India's Shilpa Medicare can make 100-200 million doses of COVID-19 shot, says executive
    The Economic Times
    NewsBot
    Mar 5 5:21 AM
    Shilpa Medicare gets tentative American health regulator nod for Apremilast tablets
    The Economic Times
    NewsBot
    Nov 1, 2020 5:38 AM
    USFDA issues warning to Shilpa Medicare for CGMP violations at Telangana plant
    Moneycontrol
    NewsBot
    Oct 13, 2020 4:11 AM
    Add Shilpa Medicare, target price Rs 580: ICICI Securities
    The Economic Times
  • SHILPAMED - Related Communities

    keyboard_arrow_down
    Sun Pharmaceutical Industries Ltd. NS...
    Cipla Ltd. NSE: CIPLA | BSE: 500087 |...
    Aurobindo Pharma Ltd. NSE: AUROPHARMA...
    Biocon Ltd. NSE: BIOCON | BSE: 532523...
    Lupin Ltd. NSE: LUPIN | BSE: 500257 |...
    Dr. Reddy's Laboratories Ltd. NSE: DR...
    Glenmark Pharmaceuticals Ltd. NSE: GL...
    Divi's Laboratories Ltd. NSE: DIVISLA...
    Piramal Enterprises Ltd. NSE: PEL | B...
    Cadila Healthcare Ltd. NSE: CADILAHC ...
SOURCE: Data from D'Market via Quandl. Intraday data delayed 15 minutes.
DISCLAIMER: Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and FrontPage will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein.

PrivacyTerms
FrontPage © 2020